

“Objective of the medical Conference is to provide an update on current researches and clinical trials against lymphangiomyomatosis, as well as establish the best strategic steps to take to work towards an effective treatment of the disease in the shortest possible timeframe”

### 1<sup>st</sup> October 2010

Conference venue: Sala Ajace, Piazza Libertà, Udine

2.00-2.30 pm: **Registration & Coffee**

2.30-3.00 pm: **Saluto alle autorità**

**Bruno Bembi**

Centro di Coordinamento delle Malattie Rare FVG  
“Why we need to organize National and International Networks for Rare Diseases”

3.00-3.30 pm: **Patient Session I - Lam Italia Iris Bassi**

3.30-4.00 pm: **Amy Farber**

LAM Treatment Alliance “LTA, Accelerating Global Progress & Patient-Centered Initiatives”

#### Lam Research Session I

4.00-4.30 pm: **Jeanine D'Armiento**

“Insights into the Pathogenesis of LAM”

4.30-5.00 pm: Lam Treatment Alliance “Accelerating Global Progress, Drug Development and Genomics for LAM”

5.00-5.30 pm: **Discussion**

5.30-6.00 pm: **Buffet**

### 2<sup>nd</sup> October 2010

Conference venue: Auditorium, Palazzo della Regione FVG, Via Sabbadini, Udine

#### Lam Research Session I / Chairs Elisabeth Henske - Franco Bonetti

9.00-9.30 am: **Elisabeth Henske**

“Developing Novel Treatment Strategies for LAM: from Bench to Bedside”

9.30-10.00 am: **Vera Krymskaya**

“Novel Therapeutic Targets for LAM: rationale and promise.”

10.00-10.30 am: **Markus Weckmann**

“Lamstatin a novel inhibitor of lymphangiogenesis is absent in LAM”

10.30-11.00 am: **Discussion**

11.00-12.30 am: **Patient Session II**

12.30-1.30 pm: **Buffet**

#### Lam Research Session II / Chairs Vera Krymskaya – Caroline Heckman

1.30-2.30 pm: **Franco Bonetti**

“Histopathology and phenotype of LAM”

2.00-2.30 pm: **Silvia Stacchiotti** Malignant PECOMA:

“Clinical behaviour and treatment option”

2.30-3.00 pm: **Graziella Pellegrini**

“Epithelial stem cells and regenerative medicine, 10 years experience”

3.00-3.30 pm: **Kameswara Rao Badri**

“Lack of exonic TSC1/TSC2 mutations is not uncommon in sporadic LAM”

3.30-4.00 pm: **Raymond S. Yeung**

“LAM: Does EMT play a role?”

4.00-4.30 pm: **Caroline Heckman**

“Lymphatic invasion and LAM”

4.30-5.00 pm: **Discussion**

5.00-6.00 pm: **Forum for clinician and Researchers only**

### 3<sup>rd</sup> October 2010

Conference venue: Sala Ajace, Piazza Libertà, Udine

#### Lam Clinical Session / Chairs Dr Sergio Harari – Dr Simon Johnson

9.00-9.30 am: **Sergio Harari**

“An integrated clinical approach to Lam”

9.30-10.00 am: **Joel Moss**

“Clinical and Molecular Insights into LAM”

10.00-10.30 am: **Francis Mc Cormack**

“Clinical Trials in LAM”

10.30-11.00 am: **Simon Johnson**

“Translational studies in LAM: from molecule to woman”

11.00-11.30 am: **Federico Rea**

“Lung transplantation for lymphangiomyomatosis”

11.30-12.00 am: **Domenica Taruscio**

Affiliazione: Director of the National Centre for Rare Diseases (Istituto Superiore di Sanità)  
“National and international initiatives to improve collaborations on rare diseases”

12.00-12.30 am: **Patient Session III**

12.30-1.30 am: **Discussion**

1.30-1.30 pm: **Buffet**

#### Patient sessions I, II, III will be presented by:

**Corine Durand - FLAM FRANCE** / Experience with lam in France

**AELAM SPAIN** / Experience with lam in Spain

**LAM SELBSTHILFE - GERMANIA** / Experience with lam in Germany

**The LAM Foundation - USA** / Jill Releigh

**LAM Austria** / Experience with lam in Austria

**Lam Action - Gill Hollis** / Experience with lam in UK “LAM in the UK - The LAM Action Perspective”

**LAM Treatment Alliance** / “LTA, Accelerating Global Progress & Patient-Centered Initiatives” Amy Farber

**LARA Australian Lam Organization** / Experience with lam in Australia